GCM
BIS icon

Gunderson Capital Management’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Gunderson Capital Management’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,967
Closed -$918K – 62
2018
Q4 		$918K Buy
+4,967
New +$800K 4% 6

Other funds holding BIS

WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gunderson Capital Management's BIS Position: Q1 2019 in Review

Gunderson Capital Management sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2019, closing a stake of 4,967 shares — an estimated $918K sold.

Gunderson Capital Management first reported a position in BIS in Q4 2018 and held it in 1 quarter. The position peaked at $918K in Q4 2018. 8 funds tracked by Wall St. Rank hold BIS as of Q1 2019.

  • Gunderson Capital Management reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2019 after selling out during the quarter.
  • Gunderson Capital Management sold 4,967 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2019, an estimated $918K.
  • Gunderson Capital Management first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2018 and held it in 1 quarter.
  • Gunderson Capital Management's ProShares UltraShort NASDAQ Biotechnology position peaked at $918K in Q4 2018.
  • 8 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2019.

Based on Gunderson Capital Management's 13F filing for Q1 2019, filed 14 Nov 2019.